Vascular Pharmaceuticals is pioneering a new approach to treat one of the most common complications of diabetes, diabetic nephropathy. This type of kidney disease affects individuals living with Type 1 and Type 2 diabetes, and there is currently no cure.
We aspire to help people with diabetes live longer, healthier lives. Our lead candidate, VPI-2960B, is in Phase 2 clinical trials. Studies conducted in animal models of diabetic nephropathy have shown that VPI-2690B may stop and even reverse the progression of diabetic nephropathy. We are committed to exploring the benefits of this potential breakthrough for diabetics who currently lack effective treatment options.
|News, Events and Publications|
|03/02/15||Vascular Pharmaceuticals, Inc. Completes $9.0 Million Expansion of Series A Financing •>>|
|11/14/14||Vascular Pharmaceuticals, Inc. Initiates Phase 2 Clinical Trial of VPI-2690B for Diabetic Nephropathy •>>|
|09/12/12||Vascular Pharmaceuticals, Inc. Completes $16 Million Equity Financing, Signs Agreement with Janssen Biotech, Inc. •>>|